复方甘草酸苷联合柳氮磺吡啶治疗溃疡性结肠炎的临床研究

目的探讨复方甘草酸苷联合柳氮磺吡啶治疗溃疡性结肠炎的临床疗效。方法选取2010年2月—2014年10月中国人民解放军第二五一医院消化内科收治的溃疡性结肠炎患者260例,随机分为对照组和治疗组,每组各130例。对照组患者口服柳氮磺吡啶肠溶片,1.0 g/次,4次/d。治疗组在对照组治疗基础上口服复方甘草酸苷片,2片/次,3次/d。两组均连续治疗4周。观察两组的临床疗效,同时比较治疗前后两组临床活动指数、血清白介素-6(IL-6)、白介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)的变化情况。观察两组患者的不良反应和1年内的复发情况。结果治疗后,对照组和治疗组的总有效率分别为80.00%、96.15%,两组比较差异具有统计学意义(P0.05)。治疗后,两组临床活动指数、IL-6、IL-8、TNF-α水平均显著降低,同组治疗前后差异具有统计学意义(P0.05);且治疗组这些观察指标的下降程度优于对照组,两组比较差异有统计学意义(P0.05)。治疗组1年复发率明显低于对照组,平均复发次数明显少于对照组,两组比较差异有统计学意义(P0.05)。结论复方甘草酸苷联合柳氮磺吡啶治疗溃疡性结肠炎具有较好的临床疗效,可显著抑制炎症反应,同时还可降低远期复发率,具有一定的临床推广应用价值。

Clinical study on compound glycyrrhizin combined with sulfasalazine in treatment of ulcerative colitis

Objective To investigate the clinical effect of compound glycyrrhizin combined with sulfasalazine in treatment of ulcerative colitis.Methods Patients (260 cases) with ulcerative colitis in Department of Gastroenterology of the 251st Hospital of PLA from February 2010 to October 2014 were randomly divided into control (n= 130 ) and treatment (n= 130 ) groups. The patients in the control group werepoadministered with Sulfasalazine Enteric-coated Tablets, 1.0 g/time, four times daily. The patients in the treatment group werepoadministered with Compound Glycyrrhizin Tablets on the basis of the control group, 2 tablets/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the efficacy was evaluated, and the changes of clinical activity indexes, IL-6, IL-8, and TNF-α in two groups were compared. The adverse reactions and relapse within 1 year in two groups were observed.Results After treatment, the efficacies in the control and treatment groups were 80.00% and 96.15%, respectively, and there were differences between two groups (P < 0.05). After treatment, clinical activity indexes, IL-6, IL-8, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The recurrence rate within 1 year and the average numbers of recurrence in the treatment group were obviously lower than those in the control group, and there were differences between two groups (P < 0.05).Conclusion Compound glycyrrhizin combined with sulfasalazine has clinical curative effect in treatment of ulcerative colitis, and can inhibit the inflammatory response, also can reduce long-term recurrence rate, which has a certain clinical application value.